Evidence map›Paper›PMID 35968595›Full record

ArticleZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2022

[Optimization of CD19 chimeric antigen receptor T cell establishment and observation of the killing effect in vitro and in vivo].

C X Ren, X X Chen, L Zhao, Y Tian, K L Xu, K Zhao

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 80% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

C X RenBlood Disease Institute, Xuzhou Medical University, Key Laboratory of Bone Marrow Stem Cell, Department of Hematology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou 221000, China.
X X ChenBlood Disease Institute, Xuzhou Medical University, Key Laboratory of Bone Marrow Stem Cell, Department of Hematology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou 221000, China.
L ZhaoBlood Disease Institute, Xuzhou Medical University, Key Laboratory of Bone Marrow Stem Cell, Department of Hematology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou 221000, China.
Y TianBlood Disease Institute, Xuzhou Medical University, Key Laboratory of Bone Marrow Stem Cell, Department of Hematology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou 221000, China.
K L XuBlood Disease Institute, Xuzhou Medical University, Key Laboratory of Bone Marrow Stem Cell, Department of Hematology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou 221000, China.
K ZhaoBlood Disease Institute, Xuzhou Medical University, Key Laboratory of Bone Marrow Stem Cell, Department of Hematology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou 221000, China.
Xuzhou Medical College · CN

Funding

Key Program of National Natural Science Foundation of China 81930005National Natural Science Foundation of China 81800179Postgraduate Research & Practice Innovation Program of Jiangsu Province KYCX20_2485
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Receptors, Chimeric AntigenAdaptor Proteins, Signal TransducingAnimalsAntigens, CD19CD28 AntigensImmunotherapy, AdoptiveMiceT-LymphocytesAdaptor Proteins, Signal TransducingAntigens, CD19CD28 AntigensReceptors, Chimeric AntigenB-cells lymphomaCD19Chimeric antigen receptor T cells

Identifiers

PMID35968595
PMCPMC9800219
OpenAlexW4300078763

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.